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Abstract Induction of apoptosis BJAB cells is accompanied by
the rapid cleavage of protein synthesis eukaryotic initiation
factor 4G and the appearance of a fragment of approximately
76 kDa. Inhibition of apoptotic proteases (caspases) has
previously been shown to prevent the cleavage of eukaryotic
initiation factor 4G. In MCF-7 breast carcinoma cells, which are
deficient in caspase-3, eukaryotic initiation factor 4G is not
cleaved but in vivo expression of caspase-3 restores eukaryotic
initiation factor 4G cleavage following induction of apoptosis.
Recombinant caspase-3 can also cleave eukaryotic initiation
factor 4G to yield the 76 kDa fragment both in cell extracts and
when the eukaryotic initiation factor 4G is presented in a purified
eukaryotic initiation factor 4F complex. These results indicate
that caspase-3 activity is necessary and sufficient for eukaryotic
initiation factor 4G degradation.
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1. Introduction
The mammalian polypeptide chain eukaryotic initiation fac-
tor 4G (eIF4G) plays a crucial role in the mechanism by
which the translation of all cellular mRNAs takes place by
acting as a bridge between other components of the ribosomal
initiation complex (reviewed in [1,2]). Two forms of eIF4G
have been identi¢ed, termed eIF4GI and eIF4GII [3]. eIF4GI
is a single polypeptide chain of 154 kDa [4] which exists at
least partly in the form of a trimeric complex with the mRNA
cap binding protein eIF4E and the ATP-dependent RNA heli-
case eIF4A, constituting the initiation factor eIF4F [5]. As
well as having domains for the binding of eIF4E and
eIF4A, the factor possesses binding sites for eIF3 [6] and
the poly(A) binding protein (PABP) [7^11]. Interaction of
PABP with eIF4GI may allow functional association of the
3P end of an mRNA with the 5P end [9,10]. Since it is likely
that eIF4GII has similar properties, the reason for the
existence of two di¡erent eIF4G species is not presently
understood.
The association of eIF4G with eIF4E markedly enhances
the binding of the latter to the mRNA cap [12]. This inter-
action is inhibited by the eIF4E binding proteins (4E-BPs)
which compete with eIF4G for binding to eIF4E [13^16].
Release of eIF4G from eIF4E in the presence of the binding
protein 4E-BP1 reduces the susceptibility of eIF4G to cleav-
age by the foot and mouth disease virus L protease [17],
suggesting that eIF4E may cause a conformational change
in eIF4G that exposes the L protease cleavage site.
Apoptosis (programmed cell death) involves a series of cel-
lular events resulting in characteristic morphological changes,
alterations in membrane permeabilities, the selective cleavage
of protein targets, the endonucleolytic fragmentation of DNA
and, ultimately, loss of cell viability [18^21]. A large body of
research has characterised the properties of the apoptotic pro-
teases (caspases) involved in these processes, together with the
nature of several caspase substrates that are cleaved during
the execution of the apoptotic programme [21^27]. We have
recently reported that eIF4G is very susceptible to degrada-
tion during apoptosis induced by serum deprivation, anti-Fas
(CD95) stimulation, etoposide or cycloheximide treatment in
BJAB and Jurkat lymphoma cell lines and that proteolysis of
the factor to produce distinct cleavage fragments under these
conditions is mediated by caspase activity [28,29]. Moreover,
protein synthesis is strongly inhibited under conditions of
apoptosis and, at least in the case of anti-Fas treatment,
this inhibition can be prevented by incubation with the cell
permeable caspase inhibitor, z-VAD.FMK [29]. Here, we
show that caspase-3 is both necessary and su⁄cient for cleav-
age of eIF4G and that the caspase-dependent degradation of
eIF4G is not in£uenced by the association of the latter with
eIF4E.
2. Materials and methods
2.1. Materials
Tissue culture materials were purchased from Life Technologies,
cycloheximide was obtained from Sigma-Aldrich, the caspase inhibi-
tor z-VAD.FMK was from Alexis Biochemicals and puri¢ed caspase-
3 was purchased from Autogen Bioclear (UK). Bacterial extracts con-
taining recombinant forms of caspase-1 and caspase-3 were a gift
from Dr. S. Goodbourn (St George’s Hospital Medical School, Lon-
don, UK).
2.2. Cell culture and induction of apoptosis
The EBV-negative Burkitt’s lymphoma cell line BJAB and the
breast cancer cell lines MCF-7 (caspase-3 de¢cient) and MCF-7.3.28
(stably transfected to express caspase-3) were cultured as described in
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[28] and [30,31], respectively. Apoptosis was induced with cyclohexi-
mide (100 Wg/ml) [28], tumour necrosis factor (30 ng/ml) plus cyclo-
heximide (10 Wg/ml) or staurosporine (1 WM) [30,31]. The times of
treatment are given in the individual ¢gure legends.
2.3. Preparation and analysis of cell extracts
Cytoplasmic extracts of cells were prepared for immunoblotting as
described previously [28]. Nuclei were removed by centrifugation for
5 min in a microcentrifuge at 4‡C. Samples were subjected to electro-
phoresis on sodium dodecyl sulfate (SDS) polyacrylamide gels and the
proteins transferred to polyvinylidene di£uoride membranes (Milli-
pore) using a semi-dry blotting apparatus (Hoefer). Equal amounts
of total protein were loaded on the gels. Antibodies to a region of
eIF4G encompassing amino acids 920^1396 and to K-fodrin were as
described previously [28^31]. Immunoblots were either developed us-
ing alkaline phosphatase-linked secondary antibodies with nitroblue
tetrazolium as substrate or were analysed by enhanced chemilumines-
cence.
2.4. Preparation of recombinant proteins
The human eIF4G cDNA sequence from plasmid pSKHFC1 [32]
was subcloned as an EcoRI fragment into pFastBac (Life Technolo-
gies). The Xenopus eIF4E cDNA sequence from plasmid pKS-41b (a
kind gift from Dr. N. Sonenberg, McGill University, Montreal, Can-
ada) was modi¢ed using the oligonucleotide sequence 5P-TCA CAT
CCA TCT ACC ATG GCG GCC GTG GAA-3P to include a NcoI
site at the initiator AUG and then subcloned into pFastBacHtA (Life
Technologies) as an NcoI-EcoRI fragment. Recombinant baculovi-
ruses were then constructed from these shuttle vectors as per the
manufacturer’s instructions (Life Technologies). Initiation factor
eIF4F was puri¢ed from Sf9 insect cells co-infected for 72 h with
recombinant baculoviruses expressing eIF4G and eIF4E. The eIF4A
component of this eIF4F originated from the insect cells. Cells were
harvested and resuspended in 5 ml per 100 ml culture of lysis bu¡er
(50 mM (3-(N-morpholino))propanesulfonic acid (MOPS), pH 7.2,
100 mM NaCl, 5 mM EDTA, 5 mM ethylene glycol-bis(L-aminoethyl
ether) (EGTA), 5 mM DTT, 1 mM phenylmethylsulfonyl £uoride
(PMSF), 1 mM benzamidine, 10 WM E-64 and 10 Wg/ml leupeptin),
lysed by the addition of IGEPAL (Sigma) to 1% (by volume) and
clari¢ed by centrifugation at 15 000Ug for 20 min at 4‡C. The super-
natant was applied to 7-methyl-guanosine triphosphate (m7)GTP-
Sepharose resin, washed in bu¡er (20 mM MOPS, pH 7.2, 50 mM
NaCl, 5 mM EDTA, 5 mM EGTA, 5 mM DTT, 1 mM PMSF, 1 mM
benzamidine, 10 WM E-64 and 10 Wg/ml leupeptin) and uncomplexed
eIF4E and the eIF4F complex were eluted with 0.1 mM m7GTP in the
same bu¡er. eIF4F was separated from uncomplexed eIF4E by chro-
matography using MonoQ FPLC resin (Pharmacia) using a linear
gradient of 50^500 mM NaCl (in 20 mM MOPS, pH 7.2, 100 WM
EDTA, 2 mM EGTA, 0.05% (by volume) Tween-20, 7 mM 2-mer-
captoethanol), as described previously [33]. Recombinant 4E-BP1 and
foot and mouth disease virus L protease were prepared as described
previously [17,33,34].
3. Results
3.1. Caspase-3 activity is required for cleavage of eIF4G in vivo
We have previously reported that the caspase inhibitors z-
VAD.FMK and z-DEVD.FMK block the cleavage of eIF4G
in both BJAB and Jurkat cells treated with several di¡erent
inducers of apoptosis [28,29]. These data suggested that casp-
ase activity was required for eIF4G cleavage, but did not
establish whether the initiation factor was a direct substrate
for any particular caspase. We have taken advantage of the
existence of the MCF-7 cell line that is de¢cient in caspase-3
[30,31] to investigate the requirement for this enzyme in vivo
during the cellular response to two di¡erent treatments that
induce apoptosis. Fig. 1 shows that in MCF-7 cells, neither
treatment with the combination of tumour necrosis factor
(TNF) plus cycloheximide (lane 1 versus lanes 2 and 3) nor
exposure to the protein kinase inhibitor staurosporine (lane 1
versus lanes 4 and 5) caused any loss of full-length eIF4G or
the appearance of the 76 kDa fragment. In contrast, both
conditions enhanced the degradation of the 240 kDa structur-
al protein K-fodrin to give a 150 kDa product, which is medi-
ated by the activation of calpain and not caspases [30]. How-
ever, when MCF-7 cells that were stably transfected to express
caspase-3 (MCF-7.3.28) were subjected to the same treat-
ments, eIF4G was cleaved to give the 76 kDa product (Fig.
1, lane 6 versus lanes 7 and 8 and lanes 9 and 10) and K-
fodrin, a known substrate for caspase-3, was cleaved to yield a
characteristic 120 kDa fragment [30]. Together, these data
indicate that caspase-3 activity is essential for the cleavage
of eIF4G in response to inducers of apoptosis. The 76 kDa
fragment appears to be relatively unstable in these cells since
its level declined substantially between 8 and 16 h after in-
duction of apoptosis (Fig. 1, lane 7 versus lane 8 and lane 9
vsrsus lane 10).
Although caspase-3 is essential for eIF4G breakdown dur-
ing apoptosis, the data presented in Fig. 1 do not tell us
whether there is direct cleavage of the initiation factor by
this enzyme. To investigate this, initially, we incubated cyto-
plasmic extracts of BJAB cells in vitro with bacterial cell ex-
tracts expressing either recombinant caspase-3 or recombinant
caspase-1. Under these conditions, caspase-3 caused the cleav-
age of eIF4G to yield the characteristic 76 kDa fragment (Fig.
2A, lane 1 versus lane 3 and Fig. 2B, lane 3 versus lane 5). In
contrast, incubation with caspase-1 (Fig. 2A, lane 1 versus
lane 2) or a control bacterial extract (data not shown) failed
to induce cleavage of eIF4G and did not a¡ect the ability of
caspase-3 to cleave the factor (Fig. 2A, lane 3 versus lane 4).
We have also examined the e¡ect of these bacterially ex-
pressed caspases on the cleavage of recombinant, puri¢ed
eIF4G, co-expressed in baculovirus-infected insect cells with
eIF4E. These data indicate that the bacterial cell extract ex-
pressing recombinant caspase-3 will cleave eIF4G presented in
this form to yield the 76 kDa fragment (Fig. 2A, lane 5 versus
lane 7 and Fig. 2B, lane 7 versus lane 8), but again, no speci¢c
cleavage was observed with caspase-1 (Fig. 2A, lane 5 versus
lane 6). We have also used highly puri¢ed caspase-3 in these
Fig. 1. Caspase-3-dependence of eIF4G cleavage in MCF-7 breast
cancer cells. MCF-7 (caspase-3 de¢cient) and MCF-7.3.28 cells (sta-
bly transfected to express caspase-3) were incubated with or without
TNF-K plus cycloheximide or staurosporine for the times indicated.
Total cytoplasmic extracts were prepared and analysed by immuno-
blotting for eIF4G and K-fodrin. The bands corresponding to full-
length eIF4G, its 76 kDa cleavage product and K-fodrin and its
150 and 120 kDa cleavage products are indicated. The data are
from a single experiment but are representative of those obtained
on three separate occasions.
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assays. The data in Fig. 2B (lane 3 versus lane 6 and lane 7
versus lane 9) indicate that puri¢ed caspase-3 will cleave the
eIF4G that is in cytoplasmic extracts or is presented as a
puri¢ed protein. A direct comparison of the products of casp-
ase-3-mediated eIF4G cleavage in vitro with those that appear
in apoptotic cells shows precise electrophoretic co-migration
of the 76 kDa protein (Fig. 2B, lanes 4^6). However, as shown
in Fig. 2A and B, additional products of eIF4G cleavage with
apparent sizes of 150 and 120 kDa were evident when puri¢ed
eIF4F was used as the substrate for caspase-3. These novel
fragments of eIF4G constitute only minor immunoreactive
bands when apoptotic cell extracts or control cell extracts
incubated with caspase-3 are analysed, suggesting that the
larger fragments are unstable in vivo. Using antiserum to a
di¡erent region of eIF4G, similar incomplete cleavage with
caspase-3 in vitro was seen when a ribosomal salt wash frac-
tion from HeLa cells was used as a source of eIF4G [35]. To
address this in more detail, we examined the time course of
appearance of the degradation products of eIF4G when puri-
¢ed eIF4F was incubated with caspase-3 in vitro (Fig. 2C).
Under these assay conditions, eIF4G was cleaved within 15
min to yield the 150, 120 and 76 kDa products and there was
an obvious precursor-product relationship between the full-
length protein and these fragments.
Fig. 2. Cleavage of eIF4G by recombinant caspase-3 in vitro and
comparison of the products with those observed in apoptotic cells.
A: A cytoplasmic extract was prepared from control BJAB cells
and initiation factor eIF4F was puri¢ed from insect cells infected
with recombinant baculoviruses expressing human eIF4G and
eIF4E, as described in Section 2. Each preparation was incubated
for 1 h at 30‡C with or without extracts from bacteria expressing
caspase-1 or caspase-3. The samples were then analysed for the in-
tegrity of eIF4G by SDS gel electrophoresis and immunoblotting.
Molecular mass markers are indicated on the left and the bands
corresponding to full-length eIF4G and its speci¢c cleavage products
are indicated on the right. B: Cytoplasmic extracts were prepared
from control and apoptotic (8 h cycloheximide-treated) BJAB cells
and eIF4F was puri¢ed from baculovirus-infected insect cells as
above. Samples were incubated with or without extracts from bacte-
ria expressing caspase-3 or with puri¢ed recombinant caspase-3 (20
Wg/ml), as indicated, for 1 h at 30‡C and then analysed as in A.
Lanes 1 and 2: caspase-3 preparations alone; lanes 3, 5 and 6: con-
trol cell extract; lane 4: apoptotic cell extract; lanes 7^9: puri¢ed
eIF4F. Molecular mass markers are indicated on the left and the
bands corresponding to full-length eIF4G and its speci¢c cleavage
products are indicated on the right. C: Puri¢ed eIF4F (containing
approximately 1 Wg/ml of eIF4G) was incubated in the absence
(lower panel) or presence (upper panel) of puri¢ed caspase-3 (5 Wg/
ml) for the times indicated. The samples were then analysed for the
integrity of eIF4G by SDS gel electrophoresis and immunoblotting.
Bands corresponding to full-length eIF4G and its speci¢c cleavage
products are indicated on the right. These data are from a single ex-
periment but are representative of those obtained on three separate
occasions.
Fig. 3. Cleavage of eIF4G by caspase-3 is not inhibited by 4E-BP1.
A: Initiation factor eIF4F (containing approximately 1 Wg/ml
eIF4G) was puri¢ed from baculovirus-infected insect cells as in Fig.
2 and pre-incubated alone or with recombinant 4E-BP1 (0.5, 2.5
and 5 Wg/ml) for 10 min and then incubated for 30 min with or
without caspase-3 (5 Wg/ml) at 30‡C, as indicated. The samples were
then analysed for the integrity of eIF4G by SDS gel electrophoresis
and immunoblotting. Molecular mass markers and the bands corre-
sponding to full-length eIF4G and its speci¢c in vitro cleavage
products are indicated. B: Puri¢ed eIF4F (containing approximately
0.4 Wg/ml eIF4G) was pre-incubated in the absence or presence of
4E-BP1 (25 Wg/ml) or the caspase inhibitor z-VAD.FMK (100 WM)
for 10 min at 30‡C as indicated and was then further incubated for
1 h at 30‡C with or without caspase-3 (20 Wg/ml) or foot and
mouth disease virus L protease (0.03 Wg/ml). The samples were ana-
lysed as in A. Bands corresponding to full-length eIF4G, the C-ter-
minal cleavage product generated by L protease (Ct) and the casp-
ase-speci¢c cleavage products are indicated. These data are from a
single experiment but are representative of those obtained on three
separate occasions.
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3.2. The eIF4E binding protein 4E-BP1 does not prevent
cleavage of eIF4G by caspase-3 in vitro
Previously, we have shown that the proteolytic cleavage of
eIF4G by the foot and mouth disease virus L protease was
prevented by the eIF4E binding protein 4E-BP1 in the retic-
ulocyte lysate system [17]. These data suggested that the L
protease cleavage site was inaccessible until a change in con-
formation of eIF4G was induced by the binding of eIF4E. We
have used the in vitro cleavage system described in Fig. 2 to
investigate whether the ability of 4E-BP1 to compete with
eIF4G for binding to eIF4E alters the susceptibility of
eIF4G to degradation by caspase-3. Fig. 3 shows that incu-
bation of recombinant eIF4G with puri¢ed caspase-3 in vitro
yielded the characteristic 150, 120 and 76 kDa cleavage frag-
ments (Fig. 3A, lane 1 versus lane 2 and Fig. 3B, lane 1 versus
lane 4). Addition of 4E-BP1 at concentrations of up to 5 Wg/
ml neither enhanced nor inhibited the ability of caspase-3 to
cleave eIF4G in vitro (Fig. 3A, lane 2 versus lanes 3^5 and
Fig. 3B, lane 4 versus lane 5). The caspase-3-dependence was
demonstrated by the ¢nding that z-VAD.FMK completely
prevented the cleavage of eIF4G (Fig. 3B, lane 5 vrsus lane
6). To demonstrate that 4E-BP1 was active in these assays, we
monitored the e¡ect of L protease on the cleavage of eIF4G.
Under the same assay conditions, 4E-BP1 was able to inhibit
the appearance of the distinct Ct fragment generated by L
protease cleavage [17] (Fig. 3B, lane 2 versus lane 3).
4. Discussion
Recently, we and others [28,29,35] have shown that protein
synthesis initiation factor eIF4G is a target for caspase-medi-
ated cleavage during apoptosis. Similar results were obtained
when the integrity of the second form of eIF4G, eIF4GII [3],
was analysed with speci¢c antisera (M. Bushell and S. Morley,
data not shown). In this paper, we have presented in vivo data
indicating that eIF4G cleavage during apoptosis requires the
participation of caspase-3 (Fig. 1). MCF-7 cells lacking this
enzyme due to a functional deletion of the CASP-3 gene were
unable to degrade eIF4G in response to treatment with TNF-
K plus cycloheximide or staurosporine, although they can
undergo some other aspects of apoptosis under these condi-
tions [31]. Transfection and stable expression of caspase-3
restored the eIF4G cleavage activity. Although MCF-7 cells
also lack some other caspase activities [30,31], caspase-3 alone
is su⁄cient in vitro to produce the same 76 kDa eIF4G cleav-
age fragment as is observed in apoptotic BJAB, MCF-7.3.28
or Jurkat cells [28,29]. The enzyme also resulted in the appear-
ance of larger fragments with apparent sizes of approximately
150 and 120 kDa. These fragments of eIF4G, which also
appear in vivo [28,35], are less prominent than the 76 kDa
product and are probably transient intermediates in the for-
mation of the 76 kDa protein (Fig. 2 and data not shown).
The conclusion that caspase-3 is both necessary and su⁄cient
to cause site-speci¢c proteolysis of eIF4G is consistent with
our previous evidence that the caspase-3 inhibitor, z-
DEVD.FMK, is able to prevent eIF4G cleavage in vivo
[28,29]. Another recent study has also reported that caspase-
3 is able to cleave eIF4G in vitro in preparations of initiation
factors from HeLa cells [35].
In view of the inhibitory e¡ect of recombinant 4E-BP1 to-
wards cleavage of eIF4G mediated by the Foot-and-Mouth-
Disease Virus L protease ([17] and Fig. 3B), we tested whether
the same would be true for caspase-3-induced cleavage. A
preparation of 4E-BP1 which was capable of protecting
eIF4G from L protease-mediated degradation had no e¡ect
on the characteristic pattern of eIF4G cleavage caused by
caspase-3. This suggests that the association of eIF4E with
eIF4G is not required for the latter to be a substrate for
caspase-3, although it does enhance the ability of eIF4G to
be cleaved by L protease. The two enzymes utilise distinct
cleavage sites in the eIF4G sequence (M. Bushell et al., manu-
script submitted) and produce proteolytic fragments that are
clearly distinguishable (Fig. 3B). It therefore seems likely that
only the L protease site and not the caspase-3 site(s) is ren-
dered more exposed by the binding of eIF4E to eIF4G.
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